Asundexian (BAY2433334)
20604
Phase 3 small_molecule completed
Quick answer
Asundexian (BAY2433334) for Prevention of Ischemic Stroke is a Phase 3 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer HealthCare AG
- Indication
- Prevention of Ischemic Stroke
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed